Increased respiratory viral detection and symptom burden among patients with primary antibody deficiency: results from the BIPAD study by Ponsford, Mark J. et al.
Journal Pre-proof
Increased respiratory viral detection and symptom burden among patients with
primary antibody deficiency: results from the BIPAD study.
Mark Ponsford, MD, MRCP, Colin Price, SRN, Daniel Farewell, MMath, PhD,
Giles Greene, PhD, Catherine Moore, PhD, Michael Perry, MSc, Nicky Price, MD,
FRCPath, PhD, Simon Cottrell, PhD, Rachael Steven, PhD, Tariq El-Shanawany,
MD, MRCP, FRCPath, Emily Carne, MSc, SRN, Richard Cousins, MD, MRCP,
FRCPath, PhD, Paul Williams, MD, FRCP, FRCPath, Alexander Schaub, PhD, Cedric
Vonarburg, PhD, Stephen Jolles, MD, MRCP, FRCPath, PhD
PII: S2213-2198(20)30832-1
DOI: https://doi.org/10.1016/j.jaip.2020.08.016
Reference: JAIP 3062
To appear in: The Journal of Allergy and Clinical Immunology: In Practice
Received Date: 17 November 2019
Revised Date: 4 August 2020
Accepted Date: 5 August 2020
Please cite this article as: Ponsford M, Price C, Farewell D, Greene G, Moore C, Perry M, Price N,
Cottrell S, Steven R, El-Shanawany T, Carne E, Cousins R, Williams P, Schaub A, Vonarburg C, Jolles
S, Increased respiratory viral detection and symptom burden among patients with primary antibody
deficiency: results from the BIPAD study., The Journal of Allergy and Clinical Immunology: In Practice
(2020), doi: https://doi.org/10.1016/j.jaip.2020.08.016.
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition
of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of
record. This version will undergo additional copyediting, typesetting and review before it is published
in its final form, but we are providing this version to give early visibility of the article. Please note that,
during the production process, errors may be discovered which could affect the content, and all legal
disclaimers that apply to the journal pertain.
© 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology
P a g e  | 1   A study to determine the Burden of upper airway Infection in Patients with Antibody Deficiency 
(BIPAD) 
Increased respiratory viral detection and symptom burden among patients with primary antibody 1 
deficiency: results from the BIPAD study. 2 
Authors: 3 
Mark Ponsford* MD, MRCP- Immunodeficiency Centre for Wales, University Hospital of Wales, 4 
Cardiff, UK; Tenovus Institute, School of Medicine, Cardiff University. 5 
Colin Price* SRN- Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK. 6 
Daniel Farewell MMath, PhD - Division of Population Medicine, School of Medicine, College of 7 
Biomedical and Life Sciences, Cardiff University, UK. 8 
Giles Greene PhD- Division of Population Medicine, School of Medicine, College of Biomedical and 9 
Life Sciences, Cardiff University, UK. 10 
Catherine Moore PhD - Public Health Wales, Cardiff, UK. 11 
Michael Perry MSc - Public Health Wales, Cardiff, UK. 12 
Nicky Price MD, FRCPath, PhD - Public Health Wales, Cardiff, UK. 13 
Simon Cottrell PhD – Public Health Wales, Cardiff, UK. 14 
Rachael Steven PhD - Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK. 15 
Tariq El-Shanawany MD, MRCP, FRCPath - Immunodeficiency Centre for Wales, University Hospital 16 
of Wales, Cardiff, UK. 17 
Emily Carne MSc, SRN- Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, 18 
UK. 19 
Richard Cousins MD, MRCP, FRCPath, PhD- Immunodeficiency Centre for Wales, University Hospital 20 
of Wales, Cardiff, UK. 21 
Paul Williams MD, FRCP, FRCPath- Immunodeficiency Centre for Wales, University Hospital of Wales, 22 
Cardiff, UK. 23 
Alexander Schaub PhD - CSL Behring AG, Bern, Switzerland 24 
Cedric Vonarburg PhD – CSL Behring AG, Bern, Switzerland 25 
Stephen Jolles MD, MRCP, FRCPath, PhD – Immunodeficiency Centre for Wales, University Hospital 26 
of Wales, Cardiff, UK. 27 
*MP and CP contributed equally 28 
Corresponding author:  29 
Stephen Jolles, Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK. 30 
Tel 02920745814 31 
Fax 02920748383 32 
Email jollessr@cardiff.ac.uk 33 
Orcid 0000-0002-7394-6804 34 
Jo
urn
al 
Pr
-pr
oo
f
P a g e  | 2   A study to determine the Burden of upper airway Infection in Patients with Antibody Deficiency 
(BIPAD) 
 35 
Conflict of Interest Statement 36 
Mark Ponsford ponsfordm@cardiff.ac.uk MP has received support for education and 
conference attendance from Biotest, Binding Site, 
CSL Behring, and Shire. MP is supported by a Welsh 
Clinical Academic Training (WCAT) Lectureship. 
Colin Price Colin.R.Price@wales.nhs.uk  CP has received support for education, conference 
attendance, and/or consultation fees from Allergy 
Therapeutics Limited, Takeda, and CSL Behring. 
Daniel Farewell FarewellD@cardiff.ac.uk  No conflict of interest to disclose. 
Giles Green GreeneG@cardiff.ac.uk  No conflict of interest to disclose. 
Catherine Moore Catherine.Moore2@wales.nhs.uk  No conflict of interest to disclose. 
Michael Perry michael.perry@wales.nhs.uk  No conflict of interest to disclose. 
Nicky Price Sadly, NP passed away during preparation of this article. 
No known conflict of interests are known. 
Simon Cottrell Simon.Cottrell@wales.nhs.uk  No conflict of interest to disclose. 
Rachael Steven Rachael.Steven@wales.nhs.uk  No conflict of interest to disclose. 
Tariq El-Shanawany Tariq.El-shanawany@wales.nhs.uk  TE has received educational support, research 
support, speaker fees and/or consultation fees 
from Biotest, CSL, LFB and Takeda 
Emily Carne Emily.Carne@wales.nhs.uk  EC has received support to attend meetings and 
educational events from CSL Behring, Octapharma, 
Takeda, Grifols, Biotest, Pharming, and Novartis 
Richard Cousins Richard.Cousins@wales.nhs.uk No conflict of interest to disclose. 
Paul Williams PaulE.Williams@wales.nhs.uk  No conflict of interest to disclose. 
Alexander Schaub Alexander.Schaub@cslbehring.com  Alexander Schaub is an employee of CSL Behring 
AG, Freiburgstrasse 3, CH-3010 Bern, Switzerland 
Cedric Vonarburg Cedric.Vonarburg@cslbehring.com  Cédric Vonarburg is an employee of CSL Behring 
AG, Freiburgstrasse 3, CH-3010 Bern, Switzerland 
Stephen Jolles jollessr@cardiff.ac.uk  S.J. has received support from CSL Behring, Shire, 
Takeda, LFB, Biotest, Binding Site, Sanofi, GSK, UCB 
Pharma, Grifols, BPL SOBI, Weatherden, Zarodex 
and Octapharma for projects, advisory boards, 
meetings, studies, speaker and clinical trials. 
  37 
Jo
urn
al 
Pr
-pr
oo
f
P a g e  | 3   A study to determine the Burden of upper airway Infection in Patients with Antibody Deficiency 
(BIPAD) 
Abstract  38 
Background: Patients with primary antibody deficiency (PAD) are at increased risk of respiratory 39 
tract infections but our understanding of their nature and consequences remains limited. 40 
Objective: To define the symptomatic and microbial burden of upper airway infection in adults with 41 
PAD relative to age-matched controls.  42 
Methods: Prospective 12-month observational study consisting of a daily upper and lower airway 43 
symptom score alongside fortnightly nasal swab with molecular detection of 19 pathogen targets.  44 
Results: 44 patients and 42 controls (including 34 household pairs) were recruited, providing over 45 
22,500 days of symptom scores and 1,496 nasal swabs. Swab and questionnaire compliance 46 
exceeded 70%. At enrolment, 64% of patients received prophylactic antibiotics with a 34% 47 
prevalence of bronchiectasis. On average, PAD patients experienced symptomatic respiratory 48 
exacerbations every 6 days compared to 6 weeks for controls, associated with significant impairment 49 
of respiratory-specific quality of life scores. Viral detections were associated with worsening of 50 
symptom scores from a participant’s baseline. PAD patients had increased odds ratio (OR) for 51 
pathogen detection, particularly viral (OR 2.73; 95% CI: 2.09 to 3.57), specifically human rhinovirus 52 
HRV (OR 3.60; 2.53-5.13), and parainfluenza (OR 3.06; 1.25-7.50). H. influenzae and S. pneumonia 53 
were also more frequent in PAD. Young child exposure, IgM deficiency, and presence of 54 
bronchiectasis were independent risk factors for viral detection. Prophylactic antibiotic use was 55 
associated with a lower risk of bacterial detection by PCR.  56 
Conclusion: PAD patients have a significant respiratory symptom burden associated with increased 57 
viral infection frequency despite immunoglobulin replacement and prophylactic antibiotic use. This 58 
highlights a clear need for future therapeutic trials in the PAD-population, and informs future study 59 
design.  60 
 61 
 62 
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Highlights 63 
What is already known about this topic? Immunoglobulin replacement therapy (IgRT) is a central 64 
treatment for primary antibody deficiency patients with a major impact on lower airway infections, 65 
however recurrent upper airway infections remain a major challenge despite individualised IgRT 66 
dosing.   67 
What does this article add to our knowledge? This is the largest upper airway infection study in PAD 68 
over 12 months with controls and comparative national sentinel sampling data. It identifies 69 
recurrent chronic upper respiratory infection and symptoms from a restricted pathogen subset, 70 
despite frequent use of prophylactic antibiotics and individualised IgRT dosing.   71 
How does this study impact current management guidelines? The study impacts current guidelines 72 
by the identification of the key pathogens, immunological and social risk factors, the effect of 73 
prophylactic antibiotics and the requirement for novel treatments to address this unmet clinical 74 
need.  75 
 76 
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Abbreviations 88 
  89 
BIPAD Burden of Infection in Primary Antibody Deficiency 
HRV Human Rhinovirus 
ICAM-1 Intercellular adhesion molecule 1 
ILI Influenza-like illness 
IgRT Immunoglobulin replacement therapy 
PAD Primary Antibody Deficiency 
QoL Quality of Life 
RSV Respiratory Syncytial Virus 
SARSCoV2 Severe Acute Respiratory Syndrome Coronavirus 2 
SGRQ St George’s Respiratory Questionnaires 
SNOT-22 Sino-Nasal Outcome Test 
SRE Symptomatic Respiratory Exacerbation 
Jo
urn
al 
Pr
e-p
roo
f
P a g e  | 6   A study to determine the Burden of upper airway Infection in Patients with Antibody Deficiency 
(BIPAD) 
Introduction 90 
Patients with primary antibody deficiency are at increased risk of sinopulmonary infections. 91 
Antibody replacement therapy decreases the risk of mortality and pneumonia, but recurrent minor 92 
infections remain common (1-3). Decline in pulmonary function and progression to bronchiectasis in 93 
some has been reported despite immunoglobulin replacement therapy (IgRT) (4, 5). Lung 94 
involvement in PAD is a major determinant of quality of life, and development of structural and 95 
functional lung impairment is predictive of mortality (6). This has spurred optimisation of our 96 
therapeutic approach, including individualisation of IgG replacement dose and method to infection 97 
frequency (7) and long-term low-dose macrolide prophylaxis (8). A number of studies have drawn 98 
attention to respiratory viral infections in the setting of PAD (9-12). These have been limited by size 99 
(10), retrospective design (9), lack of a control group (9, 11), and vary in approach to the 100 
management of PAD. The most detailed report to date includes 6210 days of data and 54 nasal 101 
swabs, profiling the UK winter season (11). Thus, the nature, seasonality, and impact of these 102 
recurrent infections in a PAD cohort receiving optimised IgRT and high rates of macrolide prophylaxis 103 
remains poorly characterised. Greater understanding of the characteristics and pathogen spectrum 104 
of these infections experienced by antibody deficient patients will help define the limitations of 105 
current treatments and develop improved therapies.  106 
Study aims 107 
We set out to characterise the burden of infection in people with PAD and age-matched contacts, by 108 
recording pathogens detected by fortnightly nasal swabbing and daily symptoms of respiratory tract 109 
infection, collected over 52-weeks. Primary aims were to establish the feasibility of this approach 110 
and define how PAD patients differed from non-immunodeficient controls in terms of symptom 111 
severity and duration, as well as frequency of pathogen detections. Secondary aims were to 112 
investigate possible relationships between symptoms, pathogen detections, and 113 
immunocompetence to support risk stratification of patients. Finally, we used sentinel screening 114 
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data gathered over the same period to contextualise the pattern of microbial detections against 115 
pathogens circulating in the wider community.  116 
Methods 117 
Participants 118 
Patients were recruited from the Immunodeficiency Centre for Wales, Cardiff if they had a diagnosis 119 
of primary antibody deficient (PAD) and had commenced immunoglobulin replacement for > 3 120 
months with trough IgG level ≥ 5g/l. Healthy controls aged 18 years or over were recruited from 121 
household contacts of PAD participants (where possible) or independently (including medical staff). 122 
Participants were excluded if aged <18, unable to provide informed consent, or secondary causes of 123 
hypogammaglobulinemia were identified (13). All participants provided written informed consent. 124 
The study was approved by the Greater Manchester REC (15/NW/0379).  125 
Study design 126 
For this observational prospective study, participants were asked to record symptoms of respiratory 127 
tract infection on a daily basis for a 52-week period. Participants also competed spirometry 128 
alongside Sino-Nasal Outcome Test (SNOT-22) and St George’s Respiratory Questionnaires (SGRQ) at 129 
study entry, representing validated multi-dimensional measures of respiratory health status and 130 
quality of life concerning the upper and lower airways respectively (14, 15). Data collection in the 131 
BIPAD study began in August 2015 and ended in January 2018. 132 
Diary card 133 
Participants were asked to record daily symptoms using a study-specific symptom score (BIPAD-Q) 134 
based on the Jackson Scale (16). This includes upper and lower respiratory tract symptom 135 
components. A combined upper and lower airway symptom score of 0 (no symptoms) to 7 (multiple, 136 
severe symptoms) was generated by adding the scores for lower and upper respiratory tract 137 
symptoms (Figure E1). Data on antibiotic use, serum immunoglobulin levels, medical history, and 138 
demographics were also extracted from clinical records of individuals with PAD. 139 
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Nasal swabbing  140 
Following instruction, PAD patients performed nasal swabbing every two weeks over a 12-month 141 
period (marked “routine swab”). Control participants enrolled during the first 6 months of the study 142 
were asked to submit additional “acute” nasal swabs only in the event of ≥2 new symptoms. A 143 
protocol amendment was passed in April 2016, standardising all participants to the same routine 144 
collection schedule (Figure E2). Diaries and swabs were returned by post every fortnight. We have 145 
previously shown such methodology is suitable for reliable detection of respiratory viruses (17).  146 
Molecular analysis of upper respiratory swabs 147 
Respiratory pathogen screening was performed using the NxTAG® Respiratory Pathogen Panel (RPP, 148 
Luminex, Austen, US) targeting influenza A (typed to H1 and H3), Influenza B, respiratory syncytial 149 
virus (A and B), parainfluenza types 1-4, adenovirus, human metapneumovirus, 150 
rhinovirus/enterovirus, Mycoplasma pneumonia, human coronaviruses (OC43, 229E, NL63 and 151 
HKU1). A laboratory defined assay was then used to differentiate enteroviruses from rhinoviruses 152 
(18) and a triplex assay performed targeting of S. pneumoniae, H. influenzae, and M. catarrhalis. 153 
(19). An endogenous control targeting human RNAseP was used to ensure sample integrity. Samples 154 
from the study and sentinel surveillance scheme were processed following identical protocols for 155 
viral detection testing. Full methodology available in the online repository (Online Repository Text). 156 
Strain-typing of HRV was not performed. 157 
Definitions 158 
Symptomatic respiratory exacerbation (SRE) was defined by a symptom score of 2 or more occurring 159 
for ≥2 consecutive days as recorded by the patient, as previously described (11). SRE interval 160 
represents time elapsed until this score returned below 2. SREs were further defined as nasal swab 161 
positive or negative, and by the nature of pathogens detected within. To simplify analysis, pathogens 162 
were condensed into 12 types comprising 8 viruses (adenovirus, enterovirus, human 163 
metapneumovirus, influenza, parainfluenza, (non-pandemic seasonal) coronavirus, respiratory 164 
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syncytial virus, and rhinovirus) and 4 bacteria. Child contact was defined as regular contact with 165 
children aged ≤10 years for over 8 hours a day. 166 
Data handling and statistical analysis  167 
Diaries were transcribed and data curated in Microsoft Excel. Participant and swab data were 168 
analysed in GraphPad Prism version 6.07 with student T-test, Mann-Whitney U, or Fisher’s exact test 169 
as indicated. Symptom and swab data returned were analysed until point of participant withdrawal. 170 
Public Health Wales data was collated in Microsoft Excel. Linear mixed model fitting, multi-variate 171 
linear regression, and Cox regression analysis were performed using R (version 3.4.0). Results were 172 
considered statistically significant at p < 0.05.  173 
Results 174 
Study population 175 
A total of 44 PAD patients and 42 healthy controls participated in the study, of which 34 pairs co-176 
habited (Table 1). PAD incorporated a range of diagnoses (Table 2) including CVID (n=30), specific 177 
antibody deficiency (n=2), and hypogammaglobulinemia (n=2) failing to fulfil diagnostic criteria for 178 
CVID (20). Other diagnoses associated with humoral dysfunction were also represented including 179 
Good’s syndrome (n=2), and genetically defined PID  (including XLA (n=2), STAT1-Gain of function 180 
(n=1), Wiskott-Aldrich (n=1), and CD40 ligand-deficiency (n=1)), and genetically undefined combined 181 
immunodeficiency (n=3). Age, gender, and smoking status did not differ significantly between 182 
groups. 11 patients and 15 control participants had regular daily exposure to children age <8 years. 183 
Unsurprisingly, PAD patients clearly differed from controls in use of prophylactic antibiotics (56% vs 184 
0%). Azithromycin was most frequently prescribed (16 of 25 Table E1), reflecting the emerging 185 
evidence for macrolide prophylaxis in PAD and non-PAD chronic infective respiratory disease (8).  186 
 187 
 188 
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Feasibility 189 
10 PAD patients declined to participate in the study at screening, whilst all healthy controls 190 
consented. 7 patients and 4 controls withdrew from the study after completing up to 6 months of 191 
study data (overall 13% study population), including 3 PAD and 4 Control individuals who provided 192 
baseline questionnaire data but did not return swabs. Overall, we received 22,532 of a possible 193 
31,304 days symptom score data (72%) (Table 1). Compliance with routine nasal swab return was 194 
72% in PAD patients, and 78% in controls (Table 1).  195 
Symptomatic respiratory exacerbations are more frequent in PAD patients 196 
As a group, PAD-patients clearly differed from controls in respiratory symptoms. We observed 219 197 
SREs in PAD-patients, compared to 79 SREs reported by controls over 11397- and 11192-days follow-198 
up respectively. PAD patients reported greater daily symptom scores and lower weekly well-being 199 
(Figure 1A/B). The median duration of a symptom-free period in PAD patients was only 6 days (95% 200 
CI:  4 to 8), compared to 42 days (95% CI: 25 to 63) reported by controls (Figure 1C). Length of SREs 201 
was comparable between groups (Figure 1D), with median duration in PAD patients of 4 days (95% 202 
CI: 4 to 6) and 3 days in controls (95% CI: 3 to 4). Specific patient sub-groups showed a trend towards 203 
longer median SRE duration, notably those with CVID: 5 days (95% CI: 4 to 7 days), and 204 
bronchiectasis: 6 days (95% CI: 5 to 12 days). Some patients experienced prolonged respiratory 205 
symptoms, including 2 patients reporting > 180 days (both CVID, 1 with bronchiectasis). Average 206 
SNOT-22 and SGRQ scores were  20.5 and 23 points higher than controls respectively, Minimum 207 
clinically-significant differences have been reported in the context of chronic rhinosinusitis as 9 for 208 
SNOT-22 (15), and 4 to 8 for SGRQ in chronic obstructive pulmonary disease (COPD) (14). Thus, these 209 
two validated multi-dimensional questionnaires appear consistent with a repeated respiratory 210 
symptom burden leading to marked impairment of quality of life (QoL). Together this indicates a 211 
significant and chronic respiratory burden in patients with PAD featuring recurrent symptom 212 
episodes, despite medical therapy with prophylactic antibiotics and IgRT. 213 
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Pathogen detections within BIPAD 214 
We observed 436 pathogen detections in PAD patients and 198 in control nasal samples, 215 
representing 50% and 32% of total swabs submitted by these groups respectively. The effect of 216 
introducing routine nasal swab sampling for healthy controls was to increase the number of negative 217 
swabs (data not shown). Specific pathogen detection rates and odds ratios are summarised in Table 218 
3. HRV dominated, with parainfluenza also detectable at greater rate among PAD patients. Viral co-219 
detection with bacterial species was found at increased frequency in PAD relative to controls; with 220 
H. influenzae accounting for the majority. Conversely, M. catarrhalis detection was more common in 221 
control participants.  222 
To contextualise seasonality and significance of viral detection within BIPAD, we analysed patterns of 223 
circulating respiratory viruses based on results of swabs sent to the Public Health Wales (PHW) 224 
reference laboratory during the BIPAD study period (Figure 2, Figure E3). Briefly, this encompasses 225 
swabs provided by sentinel general practices alert for seasonal influenza illness in the community or 226 
tested following respiratory symptoms during inpatient admissions at ward-based or higher-care 227 
levels. Whilst HRV appears infrequently in BIPAD controls sampled at equivalent intensity to PAD 228 
patients, both HRV and parainfluenza virus are detectable year-round amongst symptomatic adults 229 
tested for respiratory symptoms. 230 
Upper airway pathogen detection is associated with increase in acute symptom score  231 
To define the association between a positive pathogen detection and respiratory symptoms, we first 232 
quantified the average daily symptom score for the week of swab sampling, modelling an acute 233 
symptom episode as previously described (21). To account for inter-individual variation and the 234 
presence of chronically reported symptoms, any change was compared to the individual’s 12-month 235 
average symptom score. Both PAD patients and controls showed an increase in symptoms in the 7-236 
day period around a viral detection from their baseline (Figure 3A/B). Pathogen-negative swabs 237 
were associated with a symptom-free status in controls, and net improvement of symptom scores in 238 
PAD patients (Figure 3C). In order to compare long-term symptom burdens experienced by patients 239 
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and controls, we fitted a regression model interacting study groups with positive viral or bacterial 240 
detections. To account for unobserved shared exposures and the resulting lack of independence, we 241 
included a random effect for each patient-control pair (Table E2). In the absence of pathogen 242 
detections, patients had a higher background level of symptoms, comparable to those of control 243 
patients during a viral detection. During viral detection, both patients and controls experienced a 244 
similar rise in symptom burden. Considering bacterial detections, patients again showed a higher 245 
background symptom burden, but little increase in symptom scores when bacteria were detected. 246 
Controls showed a small increase when bacteria were detected, but not elevating them to the 247 
background level of the patients. 248 
Identification of risk factors for viral and bacterial detection 249 
We next performed multiple linear regression, investigating the frequency of detection of pathogens 250 
to identify if immune or clinical characteristics could help risk-stratify patients, focusing on viral 251 
detections given their greater association with respiratory symptoms. In univariate analysis, lower 252 
trough level of IgG were associated with increased viral or pathogen-positive detection rates. 253 
However, because clinical adjustment of IgG dosing was performed based on the basis of infection 254 
frequency reported during the protocol, this was excluded from subsequent multi-variate analysis 255 
(Table E3). Regular contact with young children to emerged as the single strongest risk factor for 256 
viral detection (adjusted OR 2.16, 95% CI: 1.45 to 3.22). This association was robust to inclusion and 257 
exclusion of trough IgG level. Interestingly, the presence of bronchiectasis and lower levels of IgM in 258 
serum were also independently associated with a greater rate of viral detection. Serum IgA 259 
appeared protective in uni- but not multi-variate analysis, whilst participant age had no significant 260 
impact. Prophylactic antibiotic use was associated with markedly decreased bacterial detection rates 261 
in univariate analysis (OR: 0.261; 95% CI 0.190 to 0.359) with the effect of prophylactic antibiotics on 262 
bacterial detections shown in Figure E4. 263 
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Discussion 264 
This study provides the most detailed characterisation of the symptomatology and microbial 265 
diversity within PAD patients and controls to date. Through quantification of the rate and effect of 266 
upper respiratory tract pathogen detections relative to controls, we reveal the gulf in symptom-267 
related quality of life, despite evidence-based therapies including prophylactic antibiotics (8) and 268 
IgRT (22). 269 
The most notable finding is the increased rate of detection for common circulating upper respiratory 270 
viral pathogens (notably HRV) among PAD individuals, despite current therapies. Other viral 271 
pathogens including adenovirus, respiratory syncytial virus, and non-pandemic seasonal coronavirus 272 
showed similar trends towards increased detection frequency in PAD-patients. This pattern is 273 
reminiscent of specific immune defects associated with recurrent viral susceptibility such as 274 
IFIH1/MDA5 (23, 24) and IRF7 deficiency (25). Here, we identify major risk factors including young 275 
child contact, a likely surrogate of viral pathogen exposure, (26); and defects in circulating 276 
immunoglobulin isotypes relevant for protection at the mucosal barrier. Although exceeding any 277 
previous work, it is likely sample size limited our ability to detect differential infection rates for 278 
pathogens circulating with lower prevalence in the adult community. It is also possible our pathogen 279 
detection rates represent an underestimate of true infective burden, given the adherence to a 280 
degree of social distancing already practiced by PAD patient and their households (reported 281 
informally by participants).  282 
Strengths of our study include a high compliance rate, despite the intensity and duration of the 283 
surveillance protocol. Participant drop-out over the study period was 13%, which compares 284 
favourably to prospective longitudinal studies in COPD (27). Consistent with infection, viral 285 
detections were associated with increased symptom score and independently associated with risk 286 
factors such as presence of bronchiectasis in multivariate analysis. Through use of a multiplex PCR 287 
approach, we show HRV and H. influenzae detections frequently co-occur. Although limited by lack 288 
of paired sputum cultures, this association has been robustly described in studies examining COPD-289 
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exacerbations, where co-infection is associated with greater impairment of lung function and 290 
prolonged inpatient stays (28, 29). HRV has similarly been reported to increase H. influenzae and S. 291 
pneumoniae detection rates and exacerbation risk in asthmatic children (21). A range of studies 292 
suggest dynamic relationships between HRV, H. influenzae, and the respiratory epithelium, where 293 
co-infection favours pathogen persistence and potentiates inflammation (30-32). In secondary 294 
immunodeficiency related to haematopoietic stem-cell transplantation, pre-transplant rhinovirus 295 
infection increases mortality risk (33). It highlights the need for targeted strategies to prevent or 296 
treat respiratory tract infection in PAD (34, 35). Our findings link deficiency of mucosally-active 297 
immunoglobulin isotypes to viral susceptibility, providing further support for development of 298 
nebulised therapies to help restore a humoral immune barrier (36). We have also generated an 299 
extensive biobank amenable for next generation sequencing and bioinformatic approaches to 300 
illuminate intra-household transmission dynamics (37). 301 
We believe BIPAD defines an important baseline prior to the global emergence of coronavirus 302 
disease 2019 (COVID-19). At time of writing, evidence for which immunodeficiencies are associated 303 
with increased susceptibility, severity or duration of COVID19 among immunodeficient individuals is 304 
not yet clear but will be informed by ongoing national and international studies. However, kinetic 305 
analysis of COVID-19 infection within the immunocompetent patient strongly implicates the need for 306 
a coordinated humoral immune response (38), mirroring the immunological signature of successful 307 
vaccination (39). Our finding of increased susceptibility to a range of viral pathogens in PAD, despite 308 
current therapy and independent of age, is convergent with failure of this immune response. This 309 
supports the advice for social distancing of immunodeficient patients and potentially consideration 310 
of limiting young child exposure may also be considered (40). Finally, prolonged symptom and viral 311 
detection reported in immunocompromised individuals here, and elsewhere (12), may prove 312 
relevant when considering infection control to halt ongoing transmission chains. 313 
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Summary 314 
BIPAD highlights frequently circulating viruses such as HRV and parainfluenza as dominant 315 
pathogens in PAD-patients and reveals wider susceptibility patterns. Recurrent viral infection likely 316 
contributes significantly to the recurrent respiratory burden observed despite current therapies. 317 
BIPAD highlights a clear need for future therapeutic trials in the PAD-population. By extension, it 318 
supports social distancing including consideration of limiting young child contacts for this vulnerable 319 
patient group during the COVID-19 pandemic. 320 
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Table 1: Study flowchart 456 
 457 
 Primary antibody 
deficiency (PAD) 
patients 
Controls 
Screened, n 68 42 
Declined or excluded, n (% screened) 24 (of 68 = 35%) 0 
Enrolled, n (% screened) 44 (of 68 = 65%) 42 
Household pairs enrolled, n (% group) 34 (68 of 86 = 79%) 
Baseline questionnaire completion (% total 
expected) 
• SNOT-22 
• SGRQ 
• Pulmonary function testing 
 
 
43 (of 44 = 98%) 
43 (of 44 = 98%) 
42 (of 44 = 95%) 
 
 
39 (of 42 = 93%) 
39 (of 42 = 93%) 
41 (of 42 = 98%) 
Study drop-out  7 (of 44 = 16%) 4 (of 42 = 10%) 
Total swabs returned, n 870 626 
Nasal swabs (2-weekly) compliance  
(% of total expected) 
72% (of 1144 expected) 78% (of 745 expected) 
Total daily symptom score data, days 11397 11192 
Daily questionnaire compliance (% of total 
expected) 
71% (of 16016 
expected) 
73% (of 15288 
expected) 
Compliance is shown in brackets, represented as a % of total expected. For nasal swabs received 
from controls this was calculated following protocol amendment. 
 458 
 459 
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Table 2: Participant characteristics at enrolment 463 
 464 
 PAD Patients Controls p value 
Participants enrolled 44 42 - 
Median age/ years (range). 51.5 (21-78) 51.5 (28-77) 0.785 
Female patients, n (%) 21 (47.7%) 25 (59.5%) 0.398 
Bronchiectasis present on CT, n (%) 15 (34.1%) 1 (2.38%) 0.0002 
Smoking status   0.872 
• Current smoker 3 2  
• Ex-smoker 8 11  
• Never smoker 33 29  
Prophylactic antibiotic use, n (%) 28 (63.6%) 0 (0.0 %) <0.0001 
Young child exposure > 8 hours a day 11 (25.0%) 15 (35.7%) 0.280 
Immunoglobulin replacement therapy 44 0 <0.0001 
• IVIg 20   
• SCIg 20   
• fSCIg 4   
• IgG trough level a (g/L), (range) 9.75 (6.18-15.3)   
• IgA (g/L), (range) 0.06 (0.06-4.1)   
• IgM (g/L), (range) 0.18 (0.05-5.1)   
FEV1 (L), (Interquartile range)* 2.60 (1.81-3.17) 2.90 (2.34-3.43) 0.07 
FEV1 predicted (%)b (Interquartile range)* 87.0 (69.8-99.5) 97.0 (88.5-108.5) 0.0005 
Quality of life    
SNOT-22c (Interquartile range) 28 (16.0-43.0) 8 (2.0-29.0) 0.0003 
SGRQd (Interquartile range) 29.3 (15.6-49.6) 7.89 (4.03-16.0) <0.0001 
 465 
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Table 3: Pathogen detections within BIPAD 467 
 468 
 PAD 
Patients 
(n=41) 
 
Controls 
(n=38) 
Odds Ratio 
(95% CI) 
P value 
(Fisher’s 
exact) 
Total number swabs 870  626  - - 
Total number 
pathogen detections 
per group 
(positive swab 
fraction, %) 
436 
(50.1%) 
198 
(31.6%) 
2.17  
(1.75 to 2.69) 
<0.0001 
Viral detection 
 
266 
 (30.6%) 
 
87 
(13.9%) 
 
2.73 
(2.09 to 3.57)  
<0.0001 
Bacterial detection 
 
279 
(32.1%) 
141 
(22.5%) 
1.62  
(1.28 to 2.06) 
<0.0001 
Dual positive virus 
and bacteria 
109 
(12.5%) 
30 
(4.8%) 
2.85 
(1.87 to 4.32) 
<0.0001 
     
Human Rhinovirus 
(HRV) 
179 
(20.6%) 
42 
(6.7%) 
3.60 
(2.53 to 5.13) 
<0.0001 
Coronavirus  27 
(3.1%) 
12 
(1.9%) 
1.64 
(0.824 to 3.26) 
0.188 
Parainfluenza 25 
(2.9%) 
6 
(1.0%) 
3.06 
(1.25 to 7.50) 
0.0098 
 
Human 
metapneumovirus 
16 
(1.8%) 
13 
(2.1%) 
0.883 
(0.422 to 1.85) 
0.850 
 
Influenza 13 
(1.5%) 
9 
(1.4%) 
1.04 
(0.442 to 2.45) 
1.00 
Enterovirus 10 
(1.1%) 
6 
(1.0%) 
1.20 
(0.434 to 3.32 
0.803 
Respiratory syncytial 
virus (RSV) 
7 
(0.8%) 
3 
(0.3%) 
1.68 
(0.434 to 6.54) 
0.535 
Adenovirus  7 
(0.8%) 
2 
(0.3%) 
2.53 
(0.524 to 12.2) 
0.319 
     
Haemophilus 
influenzae 
182 
(20.9%) 
28 
(4.5%) 
5.65 
(3.74 to 8.54) 
<0.0001 
Streptococcus 
pneumoniae 
44 
(5.1% 
16 
(2.6%) 
2.03 
(1.14 to 3.63) 
0.0159 
Mycoplasma 0 0 - - 
Moraxella catarrhalis 115 
(13.2%) 
110 
(17.6%) 
0.715 
(0.538 to 0.950) 
0.0229 
 469 
 470 
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Figure and Table Legends 473 
Figure 1: Participant reported symptom scores 474 
Participants self-reported A: overall wellbeing on a weekly basis using VAS scale (0-100, 475 
with 100 being best possible) and B: daily respiratory symptom score (BIPAD-Q; a score of 7 476 
denotes multiple and maximal symptoms). C: Duration in days for which participants were 477 
without significant respiratory symptoms, approximating to time spent “well” D: Length of 478 
time for which each symptomatic exacerbation persists. PAD patients- Red, Controls- Blue.  479 
Figure 2: BIPAD and PHW detections of selected pathogens. 480 
Weekly numbers of confirmed cases of influenza A, influenza B, rhinovirus and RSV in (a) 481 
BIPAD patients and (b) BIPAD controls compared to (c) confirmed cases in Wales* and (d) 482 
cases confirmed in intensive care units in Wales. Case numbers are presented as rolling three-483 
week averages. The Welsh sentinel GP influenza-like illness weekly consultation rate is also 484 
provided (e). * Data predominantly (>95%) from hospital patients 485 
Figure 3: Pathogen detection and acute change from participant’s baseline score 486 
Bubble charts depicting dynamic change from patients (A) or controls (B) mean symptom 487 
score, during the 7-day period around each swab received. Solid bubbles: worsening of 488 
symptoms, hollow: improvement. C: Symptom scores by pathogen type and participant 489 
group. 490 
Table 1: Study flowchart 491 
Patient and control enrolment alongside compliance with baseline questionnaires, nasal swabs and 492 
daily symptom score questionnaires.  493 
Table 2: Participant characteristics at enrolment 494 
a
 serum IgG level measured immediately prior to next intravenous immunoglobulin infusion.  495 
b
 based on the European respiratory guidelines of 1993. c Sinonasal outcome test: a validated 496 
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measure of burden of sinusitis, with 22 items scored between 0-5, with total score of 0 (best) 497 
and 110 (worst). d St George Respiratory Questionnaire: a validated measure of respiratory-498 
related quality of life, scored between 0 (best) and 100 (worst). Median values are shown 499 
unless stated; p-values were calculated using the Mann-Whitney test for continuous variables 500 
and Fisher’s exact test for categorical variables unless otherwise stated (* indicates unpaired 501 
t-test) 502 
Table 3: Pathogen detections within BIPAD 503 
Viral and bacterial pathogen detections per group (% positive swab fraction) shown with 504 
Odds Ratio (95% CI) and p value (Fisher’s exact). 505 
 506 
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Figure 1: Participant reported symptom scores 
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Figure 2: BIPAD and PHW detections of selected pathogens. 
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Figure 3: Pathogen detection and acute change from participant’s baseline score 
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Figure E1: BIPAD-Q and example weekly scoring questionnaire. 
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Figure E2: Effect of protocol amendment on nasal swab submission 
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Figure E3: Extended viral detection patterns in BIPAD and Public Health Wales Surveillance 
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Figure E4: Effect of antibiotic prophylaxis on bacterial detections  
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